A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose

Vaccine

Volumn 30, Issue 24, 2012, Pages 3653-3665

  Richert, Laura E ^a   Servid, Amy E ^a   Harmsen, Ann L ^a   Rynda Apple, Agnieszka ^a   Han, Soo ^a   Wiley, James A ^a   Douglas, Trevor ^a   Harmsen, Allen G ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

Influenza virus; Mucosal vaccine; Nanoparticle; Ovalbumin; Tissue specific Immunity; Virus like particle

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN RECEPTOR; IMMUNOMODULATING AGENT; NANOPARTICLE; OVALBUMIN; OVALBUMIN SMALL HEAT SHOCK PROTEIN; SMALL HEAT SHOCK PROTEIN; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; BACTERIOPHAGE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SYNTHESIS; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RESPIRATORY TRACT MUCOSA; STOICHIOMETRY;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; FEMALE; INFLUENZA VACCINES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NANOPARTICLES; OVALBUMIN; RESPIRATORY MUCOSA; TIME FACTORS; VACCINATION; VACCINES, CONJUGATE;

EID: 84861000568     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.035     Document Type: Article

References (58)

1. Selin L.K., Brehm M.A., Naumov Y.N., Cornberg M., Kim S.K., Clute S.C., et al. Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol Rev 2006, 211(June):164-181.
2. Goulding J., Snelgrove R., Saldana J., Didierlaurent A., Cavanagh M., Gwyer E., et al. Respiratory infections: do we ever recover?. Proc Am Thorac Soc 2007, 4(December (8)):618-625.
3. Kamradt T., Goggel R., Erb K.J. Induction exacerbation and inhibition of allergic and autoimmune diseases by infection. Trends Immunol 2005, 26(May (5)):260-267.
4. Walzl G., Tafuro S., Moss P., Openshaw P.J., Hussell T. Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology. J Exp Med 2000, 192(November (9)):1317-1326.
5. Wiley J.A., Richert L.E., Swain S.D., Harmsen A., Barnard D.L., Randall T.D., et al. Inducible Bronchus-associated lymphoid tissue elicited by a protein cage nanoparticle enhances protection in mice against diverse respiratory viruses. PLoS One 2009, 4(9):e7142.
6. Holt P.G. Development of bronchus associated lymphoid tissue (BALT) in human lung disease: a normal host defence mechanism awaiting therapeutic exploitation?. Thorax 1993, 48(November (11)):1097-1098.
7. Pabst R., Tschernig T. Bronchus-associated lymphoid tissue: an entry site for antigens for successful mucosal vaccinations?. Am J Respir Cell Mol Biol 2010, 43(August (2)):137-141.
8. Tschernig T., Pabst R. What is the clinical relevance of different lung compartments?. BMC Pulm Med 2009, 9:39.
9. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(April (4 Suppl.)):S45-S53.
10. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59(January (1)):1-15.
11. Belshe R., Lee M.S., Walker R.E., Stoddard J., Mendelman P.M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 2004, 3(December (6)):643-654.
12. Nochi T. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 2010, 9(7):572-578.
13. Heegaard P.M.H. Dendrimers for vaccine and immunostimulatory uses. A review. Bioconjug Chem 2010, 21(3):405-418.
14. Stano A. PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine 2010.
15. Jegerlehner A. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002, 20(25-26):3104.
16. Peacey M. Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation. Biotechnology and bioengineering 2007, 98(5):968-977.
17. Chen Z. Protective immune response in mice vaccinated with a recombinant adenovirus containing capsid precursor polypeptide P1, nonstructural protein 2A and 3C protease genes (P12A3C) of encephalomyocarditis virus. Vaccine 2008, 26(4):573.
18. Brennan F.R. Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice. J Virol 1999, 73(2):930.
19. Caldeira J.C. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010, 28(27):4384.
20. Manayani D.J. A viral nanoparticle with dual function as an anthrax antitoxin and vaccine. PLoS pathog 2007, 3(10):e142.
21. Jennings G.T. The coming of age of virus-like particle vaccines. Biol Chem 2008, 389(5):521-536.
22. Lenz P., Day P.M., Pang Y.Y., Frye S.A., Jensen P.N., Lowy D.R., et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001, 166(May (9)):5346-5355.
23. Lenz P., Thompson C.D., Day P.M., Bacot S.M., Lowy D.R., Schiller J.T. Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells. Clin Immunol 2003, 106(March (3)):231-237.
24. Savard C., Guerin A., Drouin K., Bolduc M., Laliberte-Gagne M.E., Dumas M.C., et al. Improvement of the trivalent inactivated flu vaccine using PapMV nanoparticles. PLoS One 2011, 6(6):e21522.
25. Lacasse P., Denis J., Lapointe R., Leclerc D., Lamarre A. Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation. J Virol 2008, 82(January (2)):785-794.
26. Acosta-Ramirez E., Perez-Flores R., Majeau N., Pastelin-Palacios R., Gil-Cruz C., Ramirez-Saldana M., et al. Translating innate response into long-lasting antibody response by the intrinsic antigen-adjuvant properties of papaya mosaic virus. Immunology 2008, 124(June (2)):186-197.
27. Landry N., Ward B.J., Trepanier S., Montomoli E., Dargis M., Lapini G., et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010, 5(12):e15559.
28. Roldao A., Mellado M.C., Castilho L.R., Carrondo M.J., Alves P.M. Virus-like particles in vaccine development. Expert Rev Vaccines 2010, 9(October 10):1149-1176.
29. Huang Z., Elkin G., Maloney B.J., Beuhner N., Arntzen C.J., Thanavala Y., et al. Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 2005, 23(March (15)):1851-1858.
30. Kim K.K., Kim R., Kim S.H. Crystal structure of a small heat-shock protein. Nature 1998, 394(August (6693)):595-599.
31. Kim R., Kim K.K., Yokota H., Kim S.H. Small heat shock protein of Methanococcus jannaschii, a hyperthermophile. Proc Natl Acad Sci USA 1998, 95(August (16)):9129-9133.
32. Flenniken M.L., Willits D.A., Harmsen A.L., Liepold L.O., Harmsen A.G., Young M.J., et al. Melanoma and lymphocyte cell-specific targeting incorporated into a heat shock protein cage architecture. Chem Biol 2006, 13(February (2)):161-170.
33. Flenniken M.L., Willits D.A., Brumfield S., Young M.J., Douglas T. The small heat shock protein cage from Methanococcus jannaschii is a versatile nanoscale platform for genetic and chemical modification. Nano Lett 2003, 3(11):1573-1576.
34. Kaiser C.R., Flenniken M.L., Gillitzer E., Harmsen A.L., Harmsen A.G., Jutila M.A., et al. Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int J Nanomed 2007, 2(4):715-733.
35. Liepold L.O. Supramolecular protein cage composite MR contrast agents with extremely efficient relaxivity properties. Nano Lett 2009, 9(12):4520-4526.
36. Abedin M.J., Liepold L., Suci P., Young M., Douglas T. Synthesis of a cross-linked branched polymer network in the interior of a protein cage. J Am Chem Soc 2009, 131(12):4346-4354.
37. Gupta S.S. Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. Bioconjug Chem 2005, 16(6):1572-1579.
38. Chatterji A. Chemical conjugation of heterologous proteins on the surface of cowpea mosaic virus. Bioconjug Chem 2004, 15(4):807-813.
39. Kang S., Uchida M., O'Neil A., Li R., Prevelige P.E., Douglas T. Implementation of p22 viral capsids as nanoplatforms. Biomacromolecules 2010, 11(October 10):2804-2809.
40. Prevelige P.E., Thomas D., King J. Scaffolding protein regulates the polymerization of P22 coat subunits into icosahedral shells in vitro. J Mol Biol 1988, 202(August (4)):743-757.
41. Whitaker J.R. An absolute method for protein determination based on difference in absorbance at 235 and 280nm. Anal Biochem 1980, 109(1):156.
42. Hansen R.E. Quantification of protein thiols and dithiols in the picomolar range using sodium borohydride and 4, 4'-dithiodipyridine. Anal Biochem 2007, 363(1):77.
43. Martos G. Egg white ovalbumin digestion mimicking physiological conditions. J Agric Food Chem 2010, 58(9):5640-5648.
44. Moyron-Quiroz J.E., Rangel-Moreno J., Hartson L., Kusser K., Tighe M.P., Klonowski K.D., et al. Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 2006, 25(October (4)):643-654.
45. Matzinger P., Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev Immunol 2011, 11(March 3):221-230.
46. Moyron-Quiroz J.E., Rangel-Moreno J., Kusser K., Hartson L., Sprague F., Goodrich S., et al. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004, 10(September (9)):927-934.
47. Matzinger P. Friendly and dangerous signals: is the tissue in control?. Nat Immunol 2007, 8(January (1)):11-13.
48. Selin L.K., Brehm M.A., Kim S.K., Chen H.D. Heterologous immunity and the CD8 T cell network. Springer Semin Immunopathol 2002, 24(2):149-168.
49. Selin L.K., Varga S.M., Wong I.C., Welsh R.M. Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med 1998, 188(November (9)):1705-1715.
50. Rangel-Moreno J., Carragher D.M., Misra R.S., Kusser K., Hartson L., Moquin A., et al. B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J Immunol 2008, 180(January (1)):454-463.
51. Wissinger E., Goulding J., Hussell T. Immune homeostasis in the respiratory tract and its impact on heterologous infection. Semin Immunol 2009, 21(June (3)):147-155.
52. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10(November 11):787-796.
53. Venter P.A., Dirksen A., Thomas D., Manchester M., Dawson P.E., Schneemann A. Multivalent display of proteins on viral nanoparticles using molecular recognition and chemical ligation strategies. Biomacromolecules 2011, 12(June (6)):2293-2301.
54. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 1993, 262(November (5138)):1448-1451.
55. Chackerian B., Lenz P., Lowy D.R., Schiller J.T. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 2002, 169(December (11)):6120-6126.
56. Pinschewer D.D., Perez M., Jeetendra E., Bachi T., Horvath E., Hengartner H., et al. Kinetics of protective antibodies are determined by the viral surface antigen. J Clin Invest 2004, 114(October (7)):988-993.
57. Chackerian B., Durfee M.R., Schiller J.T. Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol 2008, 180(May (9)):5816-5825.
58. Bhagawati-Prasad V.N., De Leenheer E., Keefe N.P., Ryan L.A., Carlring J., Heath A.W. CD40mAb adjuvant induces a rapid antibody response that may be beneficial in post-exposure prophylaxis. J Immune Based Ther Vaccines 2010, 8:1.